Yael P Mosse, M.D.
Yael P Mosse, M.D.
Assistant Professor of Pediatrics
Department: Pediatrics
Contact information
The Children's Hospital of Philadelphia
Colket Translational Research Building, Office 3056
3501 Civic Center Blvd.
Philadelphia, PA 19104
Colket Translational Research Building, Office 3056
3501 Civic Center Blvd.
Philadelphia, PA 19104
Office: 215-590-0965
Fax: 267-426-0685
Fax: 267-426-0685
Email:
mosse@chop.edu
mosse@chop.edu
Education:
B.A.
Hebrew University, Jerusalem, Israel, 1992.
B.A.
Smith College, 1993.
M.D.
Sackler School of Medicine, Tel Aviv, Israel, 1997.
Permanent linkB.A.
Hebrew University, Jerusalem, Israel, 1992.
B.A.
Smith College, 1993.
M.D.
Sackler School of Medicine, Tel Aviv, Israel, 1997.
Selected Publications
Mossé Yael P, Lipsitz Emily, Fox Elizabeth, Teachey David T, Maris John M, Weigel Brenda, Adamson Peter C, Ingle Mark A, Ahern Charlotte H, Blaney Susan M: Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study. Clinical cancer research : an official journal of the American Association for Cancer Research 18(21): 6058-64, Nov 2012.Carpenter E L, Haglund E A, Mace E M, Deng D, Martinez D, Wood A C, Chow A K, Weiser D A, Belcastro L T, Winter C, Bresler S C, Asgharzadeh S, Seeger R C, Zhao H, Guo R, Christensen J G, Orange J S, Pawel B R, Lemmon M A, Mossé Y P: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 31(46): 4859-67, Nov 2012.
Carpenter Erica L, Mossé Yael P: Targeting ALK in neuroblastoma--preclinical and clinical advancements. Nature Reviews Clinical Oncology 9(7): 391-9, Jul 2012.
DuBois Steven G, Chesler Louis, Groshen Susan, Hawkins Randall, Goodarzian Fariba, Shimada Hiroyuki, Yanik Greg, Tagen Michael, Stewart Clinton, Mosse Yael P, Maris John M, Tsao-Wei Denice, Marachelian Araz, Villablanca Judith G, Matthay Katherine K: Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clinical cancer research : an official journal of the American Association for Cancer Research 18(9): 2679-86, May 2012.
Bosse Kristopher R, Diskin Sharon J, Cole Kristina A, Wood Andrew C, Schnepp Robert W, Norris Geoffrey, Nguyen Le B, Jagannathan Jayanti, Laquaglia Michael, Winter Cynthia, Diamond Maura, Hou Cuiping, Attiyeh Edward F, Mosse Yael P, Pineros Vanessa, Dizin Eva, Zhang Yongqiang, Asgharzadeh Shahab, Seeger Robert C, Capasso Mario, Pawel Bruce R, Devoto Marcella, Hakonarson Hakon, Rappaport Eric F, Irminger-Finger Irmgard, Maris John M: Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer research 72(8): 2068-78, Apr 2012.
Y.P. Mosse, F.M. Balis, M.S. Lim, J Laliberte, S Voss, E Fox, R Bagatell, B.J. Weigel, P.A. Adamson, M.A. Ingle, C.H. Ahern, S.M. Blaney: Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors: A Children’s Oncology Group Phase 1 Study. ASCO Annual Meeting 2012 Notes: Selected for ASCO Annual Meeting Press Program, Best of ASCO Program, and James B Nachman Junior Faculty Award in Pediatric Oncology.
D.A. Weiser, S.C. Bresler, M. Laudenslager, E.F. Rappaport, E.L. Carpenter, M. Hogarty, P.W. McGrady, W.B. London, M.A. Lemmon, Y.P. Mosse: ALK-based therapeutic stratification of patients with neuroblastoma. Advances in Neuroblastoma Research (ANR) Meeting 2012 Notes: Selected for the Audrey Evans Award- Best Clinical Research Abstract.
E.L. Carpenter, D Deng, E.A. Haglund, L. Belcastro, R. Metcalfe-Klaw, H. Maamar, A. Raj, J.G. Christensen, Y.P. Mosse: Mechanisms of acquired resistance in crizotinib-treated neuroblastoma. Advances in Neuroblastoma Research (ANR) Meeting 2012.
Y.P. Mosse, F.M. Balis, M.S. Lim, J Laliberte, S Voss, E Fox, R Bagatell, B.J. Weigel, P.A. Adamson, M.A. Ingle, C.H. Ahern, S.M. Blaney: Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors: A Children’s Oncology Group Phase 1 Study. Advances in Neuroblastoma Research (ANR) Meeting 2012 Notes: Plenary Talk
A.C. Wood, M. Laudenslager, K. Krytska, M. Sarmady, J. Perin, E.F. Rappaport, J.M. Maris, M. Devoto, Y.P. Mosse: Identification of a new hereditary neuroblastoma predisposition locus at chromosome 2p25. Advances in Neuroblastoma Research (ANR) Meeting 2012.